The purchase will give a boost to Bristol as patent expirations weigh on sales of its oncology medicines. The company had to slash its revenue outlook this year after sales of blood cancer drug Revlimid, its third-largest revenue driver, withered in the face of generic rivals. Its top-selling blood thinner Eliquis and cancer immunotherapy blockbuster Opdivo are also scheduled to face competition from generics later this decade.
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right
Acquisition Brings KRAZATI® , a.
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics valdostadailytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from valdostadailytimes.com Daily Mail and Mail on Sunday newspapers.